2024
Prediction of nonresectability using the updated Predictive Index value model assessed by imaging and surgery in tubo-ovarian cancer: a prospective multicenter ISAAC study
MORO, Francesca, Patricia PINTO, Valentina CHIAPPA, Antonia Carla TESTA, Juan Luis ALCAZAR et. al.Základní údaje
Originální název
Prediction of nonresectability using the updated Predictive Index value model assessed by imaging and surgery in tubo-ovarian cancer: a prospective multicenter ISAAC study
Autoři
MORO, Francesca, Patricia PINTO, Valentina CHIAPPA, Antonia Carla TESTA, Juan Luis ALCAZAR, Dorella FRANCHI, Klára BENEŠOVÁ (203 Česká republika, domácí), Jiří JARKOVSKÝ (203 Česká republika, domácí), Filip FRUHAUF, Martina BORCINOVA (203 Česká republika), Andrea BURGETOVA (203 Česká republika), Martin MASEK (203 Česká republika), Lukas LAMBERT (203 Česká republika), Dagmar ALTMANOVA (203 Česká republika), Giacomo AVESANI, Camilla PANICO, Sarah ALESSI, Paola PRICOLO, Julio Vara GARCIA, Simona PALLADINO, Raffaella VIGORITO, Giuseppina CALARESO, Roman KOCIAN (203 Česká republika), Jiri SLAMA (203 Česká republika), Ailyn Mariela Vidal URBINATI, Francesco RASPAGLIESI, Anna FAGOTTI, Giovanni SCAMBIA, David CIBULA (203 Česká republika) a Daniela FISCHEROVA
Vydání
American journal of obstetrics and gynecology, NEW YORK, ELSEVIER, 2024, 0002-9378
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30214 Obstetrics and gynaecology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 8.700 v roce 2023
Kód RIV
RIV/00216224:14110/24:00138591
Organizační jednotka
Lékařská fakulta
UT WoS
001365240900001
Klíčová slova anglicky
computed tomography; laparoscopy; laparotomy; magnetic resonance; ovarian cancer; staging; ultrasonography
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 23. 1. 2025 10:31, Mgr. Tereza Miškechová
Anotace
V originále
Background: A laparoscopy-based scoring system was developed by Fagotti et al (Fagotti or Predictive Index value (PIV)score) based on the intraoperative presence or absence of carcinomatosis on predefined sites. Later, the authors updated the PIV score calculated only in the absence of one or both absolute criteria of nonresectability (mesenteric retraction and miliary carcinomatosis of the small bowel) (updated PIV model). Objective: The aim was to demonstrate the noninferiority of ultrasound to other imaging methods (contrast enhanced computed tomography (CT) and whole-body diffusion-weighted magnetic resonance imaging (WB-DWI)/MRI) in predicting nonresectable tumor (defined as residual disease >1 cm) using the updated PIV model in patients with tubo-ovarian cancer. The agreement between imaging and intraoperative findings as a reference was also calculated. Study Design: This was a European prospective multicenter observational study. We included patients with suspected tubo-ovarian carcinoma who underwent preoperative staging and prediction of nonresectability at ultrasound, CT, WB-DWI/MRI, and surgical exploration. Ultrasound and CT were mandatory index tests, while WB-DWI/MRI was an optional test (non-available in all centers). The predictors of nonresectability were suspicious mesenteric retraction and/or miliary carcinomatosis of the small bowel or if absent, a PIV >8 (updated PIV model). The PIV score ranges from 0 to 12 according to the presence of disease in 6 predefined intra-abdominal sites (great omentum, liver surface, lesser omentum/stomach/spleen, parietal peritoneum, diaphragms, bowel serosa/mesentery). The reference standard was surgical outcome, in terms of residual disease >1 cm, assessed by laparoscopy and/or laparotomy. The area under the receiver operating characteristic curve (AUC) to assess the performance of the methods in predicting nonresectability was reported. Concordance between index tests at the detection of disease at 6 predefined sites and intraoperative exploration as reference standard was also calculated using Cohen's kappa. Results: The study was between 2018 and 2022 in 5 European gynecological oncology centers. Data from 242 patients having both mandatory index tests (ultrasound and CT) were analyzed. 145/242 (59.9%) patients had no macroscopic residual tumor after surgery (R0) (5/145 laparoscopy and 140/145 laparotomy) and 17/242 (7.0%) had residual tumor <= 1 cm (R1) (laparotomy). In 80/242 patients (33.1%), the residual tumor was>1 cm (R2), 30 of them underwent laparotomy and maximum surgery was carried out, and 50/80 underwent laparoscopy only, because cytoreduction was not feasible in all of them. After excluding 18/242 (7.4%) patients operated on but not eligible for extensive surgery, the predictive performance of 3 imaging methods was analyzed in 167 women. The AUCs of all methods in discriminating between resectable and nonresectable tumor was 0.80 for ultrasound, 0.76 for CT, 0.71 for WB-DWI/MRI, and 0.90 for surgical exploration. Ultrasound had the highest agreement (Cohen's kappa ranging from 0.59 to 0.79) than CT and WB-DWI/MRI to assess all parameters included in the updated PIV model. Conclusion: Ultrasound showed noninferiority to CT and to WB-DWI/MRI in discriminating between resectable and nonresectable tumor using the updated PIV model. Ultrasound had the best agreement between imaging and intraoperative findings in the assessment of parameters included in the updated PIV model.